(SLE) was first described by Dubois in 1960.1 Since then numerous reports have appeared, the prevalence ranging from 2-8% to 11% in adults and up to 40% in children. 1-8 Although there are isolated reports of AVN occurring in patients who have not received corticosteroid therapy, in most cases this complication has developed in patients who have received hiih dose corticosteroids at some stage of the disease. It has not been established whether it is a high daily dose or the total dose which increases the risk of AVN. The pathogenesis of AVN is not fully understood, and the fact that in some cases it develops many years after the cessation of therapy suggests that other factors, as yet undetermined, are involved.'
Hungerford and Zizic noted a relationship between Raynaud's phenomenon and AVN, "l but this has not been confirmed in other reports.' 3 5 The treatment of established AVN is a major Accepted for publication 28 All 13 patients had received corticosteroid therapy at some stage of the disease, and in five immunosuppressive agents were used in addition. The mean total dose of corticosteroid therapy was 15 g (range 3-2-47-0 g), and the mean duration of therapy was two years (range four months to four years).
The daily dose of corticosteroids did not exceed 60 mg. In 10 patients AVN developed within two years of initiating corticosteroid therapy, and in the ,remaining three patients (23%) it developed between two and five years after corticosteroid treatment was started. Eight patients were receiving corticosteroid therapy at the time of diagnosis, with doses ranging from 2-5 mg to 10 mg daily. In the five patients who were not receiving corticosteroid therapy at the time the period between the cessation of corticosteroids and the development of AVN ranged from two to 10 years (mean six years). None of the patients had active SLE at the time of developing AVN.
The commonest site involved was the femoral head (92%), which was bilateral in 38% of patients at presentation. The only other sites were the humeral head in two (15%) and the talus and lunate in one patient. Surgery was confined to the hip and was performed in 11 of the 13 patients. One patient with stage 3 radiological change (1970) had an abduction osteotomy, while a further two had unipolar interposition arthroplasties. The only patient with stage 4 osteonecrosis had a total hip replacement. Core decompression was performed in the remaining patients with stage 1 and 2 radiological changes. Core decompression was performed in two patients with symptoms graded as stage 2 radiologically, and as a 'prophylactic' procedure in five patients who were asymptomatic, with no radiological changes but with a positive bone scan (opposite hip in unilateral disease). The period of follow up after surgery ranged from four months to 12 years (median 4*5 years).
Surgery was successful in all the patients who had arthroplasties, except for mild pain in one patient who had a hemiprosthesis inserted. Of the two patients who were symptomatic at the time of core decompression (radiological stage 2), one had ongoing symptoms postoperatively and has subsequently developed stage 4 radiological change. Of the five asymptomatic patients who had core decom- results from intravascular occlusion of small arterioles by fat droplets and notes the similarity of the lesion with those encountered in caisson disease, Gaucher's disease, and sickle cell anaemia.10 He also observes that the hypoxia consequent upon arterial embolism results in lymphocyte hypertrophy. Hungerford has implicated vasculitis as an additional factor,'3 but the exact pathogenesis of steroid induced AVN remains speculative.
AVN has been reported in association with cytotoxic agents23 and non-steroidal anti-inflammatory drugs (NSAIDs)9 14 used alone. All the patients in our study had received corticosteroids, and it is therefore not possible to comment on the role of the former agents in the pathogenesis of AVN.
Ethanol abuse24 25 was not a factor in this study nor were any of the patients clinically hypothyroid. 26 Our findings are in agreement with those of most other studies as regards the prevalence of AVN and the predilection for younger patients and support the view that corticosteroids have a pathogenetic role in the development of the disease. From our data it is not possible to determine whether it is the size of the daily dose or the total dose of corticosteroids that places the patients at risk. Why AVN develops months or years after cessation of corticosteroid therapy in some patients cannot be explained, nor It is suggested that a significant number of patients with clinically and radiologically undetectable AVN have a significant increase of intraosseous 27 2 pressure. 28 A prospective study with a technetium bone scan is in progress to evaluate the prevalence of asymptomatic AVN. Patients will have scans and pelvic radiology at six month intervals. Intraosseous venous pressure studies and core decompression will be offered to patients who develop positive scans even in the absence of symptoms, as good results have been claimed in early cases."1 13 14 22 27 29 It is hoped that with early detection of AVN core decompression will be developed to the point where major surgery can be avoided.28 
